Trial register facet
Trial records in primary mitochondrial myopathy and bioenergetic disorders
9 records bearing on primary mitochondrial myopathy and bioenergetic disorders.
Showing 0 records on this page
Records
9 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| MMPOWER-3 | SS-31 (elamipretide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 218 | 2022 | Moderate |
| MMPOWER-3-OLEprogramme record | SS-31 (elamipretide) | Phase 3 | Reported | Single-arm open-label | — | 2022 | Very low |
| MMPOWER-3-BIOMARKERprogramme record | SS-31 (elamipretide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| MMPOWER-3-ADHERENCEprogramme record | SS-31 (elamipretide) | Phase 3 | Reported | Observational | — | 2022 | Very low |
| MMPOWER-2 | SS-31 (elamipretide) | Phase 2 | Reported | Randomised crossover | 30 | 2018 | Moderate |
| MMPOWER-2-ELDERLYprogramme record | SS-31 (elamipretide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| MMPOWER-2-OLEprogramme record | SS-31 (elamipretide) | Phase 2 | Reported | Single-arm open-label | — | 2018 | Very low |
| MMPOWER-2-ADHERENCEprogramme record | SS-31 (elamipretide) | Phase 2 | Reported | Observational | — | 2018 | Very low |
| MMPOWER-2-BIOMARKERprogramme record | SS-31 (elamipretide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |